Sage Therapeutics Q1 2024 GAAP EPS $(1.80) Misses $(1.65) Estimate, Sales $7.902M Beat $5.658M Estimate
Portfolio Pulse from Benzinga Newsdesk
Sage Therapeutics reported Q1 2024 earnings with a GAAP EPS of $(1.80), missing the $(1.65) estimate, but sales of $7.902M exceeded the $5.658M forecast, marking a 139.89% increase from last year's $3.294M.

April 25, 2024 | 10:31 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Sage Therapeutics missed Q1 2024 EPS estimates but exceeded sales forecasts, showing significant revenue growth compared to last year.
While the EPS miss might concern some investors, the substantial beat on sales forecasts and the impressive year-over-year revenue growth could offset negative sentiment. The mixed results present a neutral short-term outlook as investors weigh the implications of earnings miss against strong sales performance.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100